Crandi

New Prevention Tools And Investment In Services Essential In The Fight

Leo Migdal
-
new prevention tools and investment in services essential in the fight

On World AIDS Day, the World Health Organization (WHO) calls on governments and partners to rapidly expand access to new WHO-approved tools including lenacapavir (LEN) to drive down infections and counter disruption to essential... Despite dramatic funding setbacks, the global HIV response has gained a remarkable momentum in 2025 with the introduction and WHO approval of twice-yearly injectable lenacapavir for HIV prevention. LEN, a highly effective, long-acting alternative to oral pills and other options, is a transformative intervention for people who face challenges with regular adherence and stigma in accessing health care. WHO released in July this year new guidelines recommending the use of lenacapavir as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention. Sharp and sudden reductions in international funding this year led to disruptions in HIV prevention, treatment and testing services, with essential community-led programmes, including pre-exposure prophylaxis (PrEP) and harm reduction initiatives for people who... “We face significant challenges, with cuts to international funding, and prevention stalling," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

“At the same time, we have significant opportunities, with exciting new tools with the potential to change the trajectory of the HIV epidemic. Expanding access to those tools for people at risk of HIV everywhere must be priority number one for all governments and partners.” Marking World AIDS Day under the theme “Overcoming disruption, transforming the AIDS response”, WHO is urging a dual track approach – solidarity and investment in innovations to protect and empower communities most at risk. On World AIDS Day, the World Health Organization (WHO) calls on governments and partners to rapidly expand access to new WHO-approved tools including lenacapavir (LEN) to drive down infections and counter disruption to essential... Despite dramatic funding setbacks, the global HIV response has gained a remarkable momentum in 2025 with the introduction and WHO approval of twice-yearly injectable lenacapavir for HIV prevention. LEN, a highly effective, long-acting alternative to oral pills and other options, is a transformative intervention for people who face challenges with regular adherence and stigma in accessing health care.

WHO released in July this year new guidelines recommending the use of lenacapavir as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention. Sharp and sudden reductions in international funding this year led to disruptions in HIV prevention, treatment and testing services, with essential community-led programmes, including pre-exposure prophylaxis (PrEP) and harm reduction initiatives for people who... "We face significant challenges, with cuts to international funding, and prevention stalling," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "At the same time, we have significant opportunities, with exciting new tools with the potential to change the trajectory of the HIV epidemic. Expanding access to those tools for people at risk of HIV everywhere must be priority number one for all governments and partners." Follow us on WhatsApp | LinkedIn for the latest headlines

On World AIDS Day 2025, the World Health Organization (WHO) highlighted the urgent need to expand access to new HIV prevention tools and strengthen investment in essential services to maintain progress in the fight... The WHO release emphasized the role of long-acting injectable lenacapavir (LEN), which was recommended in July 2025 as an additional Pre-Exposure Prophylaxis (PrEP) option. LEN offers a long-acting, twice-yearly injectable option for HIV prevention. The organization noted that reductions in international funding have disrupted HIV prevention, testing, and treatment services in many countries. This has affected access to community-led HIV programmes, including PrEP and harm reduction services for people who inject drugs. WHO stressed that the combination of new prevention tools like injectable LEN and sustained investment in essential services is essential to maintain momentum in global HIV prevention efforts and continue progress toward ending the...

A terrifying new synthetic drug mixture is showing up in U.S. emergency rooms—and doctors say it’s hitting faster and harder than anything in recent years. AI was utilized for research, writing, citation management, and editing. CALIFORNIA – President Donald Trump announced on his Truth Social app, November 9, that most Americans will receive a “tariff dividend” of at least $2,000 per person, funded from federal import-tariff revenues. A bombshell came crashing into the White House health narrative Monday when longtime cardiologist Jonathan Reiner publicly rejected the official spin on President Trump’s recent MRI, calling the explanation “laughable” and suggesting the whole... Many of us dismiss a rash as “just allergies,” “just dry skin,” or “probably nothing.”.

But doctors warn there is one rash that can turn deadly in hours, not days — and Americans rarely recognize it until it’s too late. The U.S. Department of Agriculture will begin next week to block nutrition assistance funding for states led by Democrats that have not provided data on fraud in the program, Secretary Brooke Rollins told President Donald Trump... Join our subscribers list to get the latest news On World AIDS Day, the World Health Organization (WHO) has issued a report on the state of the global HIV response, highlighting a critical intersection of significant challenges and transformative opportunities. The report underscores the urgent need to align global efforts with Sustainable Development Goal 3 (SDG 3), which aims to ensure healthy lives and promote well-being for all, including the target to end the...

Recent disruptions caused by reductions in international funding threaten to reverse decades of progress. However, the introduction of new prevention tools offers a pathway to accelerate efforts and achieve these global health targets. Sharp reductions in international funding in 2025 have led to significant disruptions in essential HIV services, directly impeding progress towards SDG 3. Community-led programmes, which are crucial for reaching vulnerable populations, have been scaled back or closed in several countries. The consequences of these funding cuts include: The HIV epidemic continues to disproportionately affect key and vulnerable populations, highlighting a significant challenge to achieving SDG 10 (Reduced Inequalities).

Stigma, discrimination, and structural barriers prevent these groups from accessing essential care. Data from 2024 reveals that these populations and their partners accounted for 49% of all new HIV infections. The elevated risk factors for these groups are stark: Addressing these disparities is fundamental to creating an equitable health response and fulfilling the promise of leaving no one behind, a core principle of the SDGs. Perspectives are commissioned from an expert and discuss the clinical practice or public health implications of a published study. The original publication must be freely available online.

Roles Conceptualization, Writing – original draft, Writing – review & editing Affiliation School of Medicine and McCourt School of Public Policy, Georgetown University, Washington, DC, United States of America Roles Conceptualization, Writing – original draft, Writing – review & editing Affiliation Independent, Washington, DC, United States of America 🔊 Listen to this listenButton1.onclick = function(){ if(responsiveVoice.isPlaying()){ responsiveVoice.cancel(); }else{ responsiveVoice.speak("On World AIDS Day, the World Health Organization (WHO) calls on governments and partners to rapidly expand access to new WHO-approved tools including lenacapavir... LEN, a highly effective, long-acting alternative to oral pills and other options, is a transformative intervention for people who face challenges with regular adherence and stigma in accessing health care.

WHO released in July this year new guidelines recommending the use of lenacapavir as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention.Sharp and sudden reductions in international funding this year led to disruptions... “We face significant challenges, with cuts to international funding, and prevention stalling,\" said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “At the same time, we have significant opportunities, with exciting new tools with the potential to change the trajectory of the HIV epidemic. Expanding access to those tools for people at risk of HIV everywhere must be priority number one for all governments and partners.”Marking World AIDS Day under the theme “Overcoming disruption, transforming the AIDS response”,... In 2024:HIV prevention efforts stagnated, with 1.3 million new infections, disproportionately impacting key and vulnerable populations; UNAIDS data reveal that almost half (49%) of new HIV infections occurred among key populations – including sex... The AIDS Vaccine Advocacy Coalition estimates that, as of October 2025, 2.5 million people who used PrEP in 2024 lost access to their medications in 2025 due solely to donor funding cuts.

Such disruptions could have far-reaching consequences for the global HIV response, jeopardizing efforts to end AIDS by 2030. Momentum for innovation “We are entering a new era of powerful innovations in HIV prevention and treatment,” said Dr Tereza Kasaeva, Director of WHO’s Department for HIV, TB, Hepatitis and STIs. “By pairing these advances with decisive action, supporting communities, and removing structural barriers, we can ensure that key and vulnerable populations have full access to life-saving services.” WHO prequalified LEN for HIV prevention on... WHO’s Collaborative Registration Procedure (CRP) supported these approvals. WHO is also working closely with partners such as CIFF, the Gates Foundation, the Global Fund to Fight AIDS, Tuberculosis and Malaria and Unitaid to enable affordable access to LEN in countries. Ensuring that long-acting HIV medicines for prevention and treatment reach priority populations must be a global priority.

Integrating HIV services into primary health careWHO emphasizes that ending the AIDS epidemic depends on a fully integrated, evidence-based and rights-driven approach under the umbrella of primary health care. WHO will continue working with partners and leaders to put those most affected at the centre of the HIV response. Despite funding setbacks, the resilience and leadership of communities offer a clear path forward. By strengthening health systems, increasing domestic investment, and protecting human rights, countries can safeguard gains and ensure no one is left behind. Source link", "UK English Female"); } }; On World AIDS Day, the World Health Organization (WHO) calls on governments and partners to rapidly expand access to new WHO-approved tools including lenacapavir (LEN) to drive down infections and counter disruption to essential...

Despite dramatic funding setbacks, the global HIV response has gained a remarkable momentum in 2025 with the introduction and WHO approval of twice-yearly injectable lenacapavir for HIV prevention. LEN, a highly effective, long-acting alternative to oral pills and other options, is a transformative intervention for people who face challenges with regular adherence and stigma in accessing health care. WHO released in July this year new guidelines recommending the use of lenacapavir as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention. Sharp and sudden reductions in international funding this year led to disruptions in HIV prevention, treatment and testing services, with essential community-led programmes, including pre-exposure prophylaxis (PrEP) and harm reduction initiatives for people who... “We face significant challenges, with cuts to international funding, and prevention stalling,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “At the same time, we have significant opportunities, with exciting new tools with the potential to change the trajectory of the HIV epidemic.

Expanding access to those tools for people at risk of HIV everywhere must be priority number one for all governments and partners.” ) On World AIDS Day, the World Health Organization (WHO) calls on governments and partners to rapidly expand access to new WHO-approved tools including lenacapavir (LEN) to drive down infections and counter disruption to... Despite dramatic funding... read full story Answer for your question of the article will be displayed here ...

People Also Search

On World AIDS Day, The World Health Organization (WHO) Calls

On World AIDS Day, the World Health Organization (WHO) calls on governments and partners to rapidly expand access to new WHO-approved tools including lenacapavir (LEN) to drive down infections and counter disruption to essential... Despite dramatic funding setbacks, the global HIV response has gained a remarkable momentum in 2025 with the introduction and WHO approval of twice-yearly injectable le...

“At The Same Time, We Have Significant Opportunities, With Exciting

“At the same time, we have significant opportunities, with exciting new tools with the potential to change the trajectory of the HIV epidemic. Expanding access to those tools for people at risk of HIV everywhere must be priority number one for all governments and partners.” Marking World AIDS Day under the theme “Overcoming disruption, transforming the AIDS response”, WHO is urging a dual track ap...

WHO Released In July This Year New Guidelines Recommending The

WHO released in July this year new guidelines recommending the use of lenacapavir as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention. Sharp and sudden reductions in international funding this year led to disruptions in HIV prevention, treatment and testing services, with essential community-led programmes, including pre-exposure prophylaxis (PrEP) and harm reduction initiat...

On World AIDS Day 2025, The World Health Organization (WHO)

On World AIDS Day 2025, the World Health Organization (WHO) highlighted the urgent need to expand access to new HIV prevention tools and strengthen investment in essential services to maintain progress in the fight... The WHO release emphasized the role of long-acting injectable lenacapavir (LEN), which was recommended in July 2025 as an additional Pre-Exposure Prophylaxis (PrEP) option. LEN offer...

A Terrifying New Synthetic Drug Mixture Is Showing Up In

A terrifying new synthetic drug mixture is showing up in U.S. emergency rooms—and doctors say it’s hitting faster and harder than anything in recent years. AI was utilized for research, writing, citation management, and editing. CALIFORNIA – President Donald Trump announced on his Truth Social app, November 9, that most Americans will receive a “tariff dividend” of at least $2,000 per person, fund...